A clinical trial published in July 2026 has demonstrated that tailored gene therapy can dramatically reduce seizures in children with rare genetic forms of epilepsy. The approach uses antisense oligonucleotides (ASOs) — short, synthetic strands of DNA-like molecules that can modify gene expression without altering the underlying genetic code.
The therapy is designed around each patient's specific mutation. Researchers sequence the child's genome, identify the faulty gene responsible for the seizures, and synthesize an ASO that corrects the expression of that gene. Because the treatment does not permanently edit the DNA, it must be administered every two to three months via intrathecal injection — directly into the cerebrospinal fluid surrounding the spinal cord.
In the trial, each child served as their own control. Researchers tracked seizure frequency, medication use, and developmental measures before and after treatment. After two years, the results showed a substantial reduction in seizure burden across the group. One of the older patients, who had experienced daily seizures since infancy, regained the ability to walk independently between doses.
This approach is part of a broader shift toward "n-of-1" precision medicine — therapies designed for a single patient or a very small group sharing the same ultra-rare mutation. While the production cost per treatment remains high, the success of this trial suggests that regulatory pathways and manufacturing processes for personalized genetic therapies are becoming viable. The findings open the door for similar approaches in other neurological conditions caused by specific genetic defects, including certain forms of autism and neurodegenerative diseases.